ArticleThe journal of headache and pain2025
Tear fluid calcitonin gene-related peptide (CGRP) is elevated during spontaneous migraine attacks - results from a pilot study.
Article in The journal of headache and pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tear fluid Calcitonin gene-related peptide in patients with idiopathic intracranial hypertension headache - a prospective case-control study.The journal of headache and pain · 2026Article
- A modern reinterpretation of the "kidney governs bone" theory: systemic regulation of the neuro-endocrine-immune network via the brain-bone axis and traditional chinese medicine intervention strategies.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCalcitonin gene-related peptide (CGRP) plays an important role in the pathophysiology of migraine. The peptide is elevated during interictal and ictal migraine and it might be a biomarker for the disease. However, CGRP detection in blood is limited by dilution and rapid degradation. Therefore, we investigated tear fluid CGRP during spontaneous migraine attacks.
methodsEpisodic migraine patients were investigated at two study days. At study day 1, tear fluid was sampled interictally ('interictal') and a thorough migraine history was conducted. At study day 2, participants were investigated during a spontaneous migraine attack. Participants were asked to call the study team when experiencing a migraine attack and to present to the outpatient headache center. After arrival, tear fluid was sampled and headache characteristics were assessed. Tear fluid CGRP levels at maximum headache intensity ('headache') and after headache improvement ('post headache') were analyzed using a commercial CGRP ELISA.
results14 female migraine patients (28.4 ± 9.3 years) were included in the analysis. At the time of maximum headache, tear fluid CGRP levels were significantly higher compared to CGRP levels at baseline and after headache resolution ('interictal': 1.89 ± 1.68 ng/ml, headache: 2.34 ± 2.20 ng/ml, post headache: 1.23 ± 0.80 ng/ml; p = 0.004). The rise of tear fluid CGRP levels was significantly higher if time since headache onset was shorter (0-3 h: +1.80 ± 1.18 ng/ml, 3-6 h: +0.13 ± 0.93 ng/ml, > 6 h: -1.15 ± 1.63 ng/ml; p = 0.017).
conclusionTear fluid CGRP levels are elevated during spontaneous migraine attacks, suggesting that the detection of CGRP in tear fluid is valid and might be a migraine biomarker in future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.